Evidence map›Paper›PMID 29963179›Full record

ArticleOncology letters2018

Safety markers for rhabdomyosarcoma cells using an

Shutong Du, Lian Meng, Lingxie Song, Pengpeng Zhang, Xi Shou, Chunxia Liu, Feng Li

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Shutong DuDepartment of Pathology, School of Medicine, Shihezi University, Shihezi, Xinjiang 832002, P.R. China.
Lian MengDepartment of Pathology, School of Medicine, Shihezi University, Shihezi, Xinjiang 832002, P.R. China.
Lingxie SongDepartment of Pathology, School of Medicine, Shihezi University, Shihezi, Xinjiang 832002, P.R. China.
Pengpeng ZhangDepartment of Pathology, School of Medicine, Shihezi University, Shihezi, Xinjiang 832002, P.R. China.
Xi ShouDepartment of Animal Experiment Center, Xinjiang Key Laboratory for Medical Animal Model Research, The First Affiliated Hospital of Xinjiang Medical University, Ürümqi, Xinjiang 830011, P.R. China.
Chunxia LiuDepartment of Pathology, School of Medicine, Shihezi University, Shihezi, Xinjiang 832002, P.R. China.
Feng LiDepartment of Pathology, School of Medicine, Shihezi University, Shihezi, Xinjiang 832002, P.R. China.
Shihezi University · CNFirst Affiliated Hospital of Xinjiang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In vivo imaging system (IVIS) is a novel and rapidly expanding technology that is widely applied in life sciences, including cell tracing. IVIS is able to quantify biological events, including tumor proliferation, through counting the number of photons emitted from a specimen. PLA802-enhanced green fluorescent protein (EGFP), PLA802-monomeric cherry fluorescent protein (mCherry), RH30-EGFP and RH30-mCherry tumor cells were injected into 18 BALB/c female nude mice subcutaneously with 5×10

Indexed as

imaging systemin vivolentivirus-enhanced green fluorescent proteinlentivirus-mCherryrhabdomyosarcoma

Identifiers

PMID29963179
PMCPMC6019945
OpenAlexW2803529439

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.